Association between Inflammatory Infiltrates and Isolated Monosomy 22/del(22q) in Meningiomas

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Domingues, Patrícia Henriques ^a,b   Teodósio, Cristina ^b   Otero, Álvaro ^c   Sousa, Pablo ^c   Ortiz, Javier ^c   de Macias, Maríal Carmen García ^b   Gonçalves, Jesús María ^c   Nieto, Ana Belén ^b   Lopes, María Celeste ^a   de Oliveira, Catarina ^a   Orfao, Alberto ^b   Tabernero, Maria Dolores ^b,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CSIC   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD33 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD63 ANTIGEN; CD69 ANTIGEN; CD74 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BID; PROTEIN KINASE LYN; PROTEIN KINASE SYK; PROTEIN TYROSINE PHOSPHATASE 1B; SOMATOMEDIN B; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; BRAIN EDEMA; CANCER RECURRENCE; CHROMOSOME 22; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFLAMMATORY INFILTRATE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MONONUCLEAR CELL; MONOSOMY; NATURAL KILLER CELL; PHENOTYPE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; FEMALE; HUMANS; INFLAMMATION; KARYOTYPE; LYMPHOCYTES; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; TRANSCRIPTOME; YOUNG ADULT;

EID: 84885047663     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074798     Document Type: Article

References (43)

1. Louis DN, Ohgaki H, Wiestler OT, Cavenee WK (2007) Meningeal Tumours. WHO Classification of Tumors of the Central Nervous System. 4 ed. Lyon, France: IARC press. 163-172.
2. Riemenschneider MJ, Perry A, Reifenberger G, (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5: 1045-1054.
3. Espinosa AB, Tabernero MD, Maillo A, Sayagues JM, Ciudad J, et al. (2006) The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse. Clin Cancer Res 12: 772-780.
4. Kalala JP, Caemaert J, De Ridder L, (2004) Primary resected meningiomas: relapses and proliferation markers. In Vivo 18: 411-416.
5. Maillo A, Orfao A, Espinosa AB, Sayagues JM, Merino M, et al. (2007) Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol 9: 438-446.
6. Tabernero MD, Maillo A, Gil-Bellosta CJ, Castrillo A, Sousa P, et al. (2009) Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol 19: 409-420.
7. Sayagues JM, Tabernero MD, Maillo A, Espinosa A, Rasillo A, et al. (2004) Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions? J Mol Diagn 6: 316-325.
8. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, et al. (2012) Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 72: 2473-2480.
9. Grund S, Schittenhelm J, Roser F, Tatagiba M, Mawrin C, et al. (2009) The microglial/macrophagic response at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol 35: 82-88.
10. Domingues PH, Teodosio C, Ortiz J, Sousa P, Otero A, et al. (2012) Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas. Am J Pathol 181: 1749-1761.
11. Jochems C, Schlom J, (2011) Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236: 567-579.
12. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, et al. (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72: 1070-1080.
13. Rossi ML, Cruz Sanchez F, Hughes JT, Esiri MM, Coakham HB, (1988) Immunocytochemical study of the cellular immune response in meningiomas. J Clin Pathol 41: 314-319.
14. García García J, Muñoz de la Espada B, Orfao de Matos A, Ciudad Pizarro J, Gómez-Alonso A, (1992) Correlación clinico-biológica y características del ADN en 74 pacientes con cáncer colorrectal (citometría de flujo de piezas en fresco) Cir Esp. 51: 16-20.
15. Paz-Bouza JI, Orfao A, Abad M, Ciudad J, Garcia MC, et al. (1994) Transrectal fine needle aspiration biopsy of the prostate combining cytomorphologic, DNA ploidy status and cell cycle distribution studies. Pathol Res Pract 190: 682-689.
16. Cruz I, Ciudad J, Cruz JJ, Ramos M, Gomez-Alonso A, et al. (2005) Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. Am J Clin Pathol 123: 66-74.
17. Matarraz S, Fernandez C, Albors M, Teodosio C, Lopez A, et al. (2011) Cell-cycle distribution of different cell compartments in normal versus reactive bone marrow: a frame of reference for the study of dysplastic hematopoiesis. Cytometry B Clin Cytom 80: 354-361.
18. Tabernero MD, Espinosa AB, Maillo A, Rebelo O, Vera JF, et al. (2007) Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas. Oncologist 12: 1225-1236.
19. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
20. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, et al. (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339: 1077-1080.
21. Montelli TC, Peracoli MT, Rogatto SR, Kaneno R, do Prado CH, et al. (2011) Genetic and modifying factors that determine the risk of brain tumors. Cent Nerv Syst Agents Med Chem 11: 8-30.
22. Ishizaki S, Kasuya Y, Kuroda F, Tanaka K, Tsuyusaki J, et al. (2012) Role of CD69 in acute lung injury. Life Sci 90: 657-665.
23. Pfistershammer K, Majdic O, Stockl J, Zlabinger G, Kirchberger S, et al. (2004) CD63 as an activation-linked T cell costimulatory element. J Immunol 173: 6000-6008.
24. Frankenberger M, Passlick B, Hofer T, Siebeck M, Maier KL, et al. (2000) Immunologic characterization of normal human pleural macrophages. Am J Respir Cell Mol Biol 23: 419-426.
25. Andreesen R, Brugger W, Scheibenbogen C, Kreutz M, Leser HG, et al. (1990) Surface phenotype analysis of human monocyte to macrophage maturation. J Leukoc Biol 47: 490-497.
26. Wang ZQ, Bapat AS, Rayanade RJ, Dagtas AS, Hoffmann MK, (2001) Interleukin-10 induces macrophage apoptosis and expression of CD16 (FcgammaRIII) whose engagement blocks the cell death programme and facilitates differentiation. Immunology 102: 331-337.
27. Pure E, Cuff CA, (2001) A crucial role for CD44 in inflammation. Trends Mol Med 7: 213-221.
28. Cui W, Ke JZ, Zhang Q, Ke HZ, Chalouni C, et al. (2006) The intracellular domain of CD44 promotes the fusion of macrophages. Blood 107: 796-805.
29. Duff MD, Mestre J, Maddali S, Yan ZP, Stapleton P, et al. (2007) Analysis of gene expression in the tumor-associated macrophage. J Surg Res 142: 119-128.
30. Kaji K, Takeshita S, Miyake K, Takai T, Kudo A, (2001) Functional association of CD9 with the Fc gamma receptors in macrophages. J Immunol 166: 3256-3265.
31. Waldhauer I, Steinle A, (2008) NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943.
32. Biswas SK, Mantovani A, (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889-896.
33. Geldhof AB, Van Ginderachter JA, Liu Y, Noel W, Raes G, et al. (2002) Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood 100: 4049-4058.
34. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, et al. (2011) IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 12: 231-238.
35. Bowdridge S, Gause WC, (2010) Regulation of alternative macrophage activation by chromatin remodeling. Nat Immunol 11: 879-881.
36. Calandra T, Roger T, (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3: 791-800.
37. Mitchell RA, (2004) Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16: 13-19.
38. Rendon BE, Willer SS, Zundel W, Mitchell RA, (2009) Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol 86: 180-185.
39. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, et al. (2000) Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89: 334-341.
40. Muramaki M, Miyake H, Yamada Y, Hara I, (2006) Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Oncol Rep 15: 253-257.
41. Fersching DM, Nagel D, Siegele B, Salat C, Heinemann V, et al. (2012) Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy. Anticancer Res 32: 2047-2058.
42. Zheng YX, Yang M, Rong TT, Yuan XL, Ma YH, et al. (2012) CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer. World J Gastroenterol 18: 2253-2261.
43. Wang XB, Tian XY, Li Y, Li B, Li Z, (2012) Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas. J Neurooncol 106: 43-51.